"uuid:ID","id","label","name","instanceType","description","rationale"
"b750ef54-74f0-4732-87e3-9d8004339c0e","StudyDesign_1","","Study Design 1","StudyDesign","The main design for the study","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated."
